What You Should Know:
- GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to revolutionize drug discovery and development.
- The platform provides biopharmaceutical companies with access to de-identified and aggregated genetic data, empowering them to accelerate the development of new therapies.
Addressing the Challenges of Drug Development
The traditional drug development process is
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
NVIDIA BioNeMo Framework Accelerates AI Drug Discovery
What You Should Know:
- NVIDIA announced widespread adoption of its open-source BioNeMo™ Framework by pharmaceutical companies, techbio innovators, and AI researchers to accelerate drug discovery and molecule design.
- The framework provides a powerful suite of tools for scaling AI models in biomolecular research, bringing supercomputing capabilities to the forefront of drug development.
Accelerating Drug Discovery with AI
The BioNeMo Framework addresses the growing need
Read More
NVentures Invests in Genesis Therapeutics’ AI Platform for Drug Development
What You Should Know:
- Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm.
- This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023.
Genesis Therapeutics Partners with NVIDIA to Advance AI-Driven Drug Discovery
Genesis Therapeutics, an AI-focused
Read More
Accenture Invests in 1910 Genetics to Accelerate AI-Powered Drug Discovery
What You Should Know:
- Accenture has made a strategic investment, through Accenture Ventures, in 1910 Genetics, a biotechnology company revolutionizing drug discovery with its AI-powered platform. Terms of the investment were not disclosed.
- The strategic collaboration will combine Accenture's expertise in scaling AI solutions with 1910 Genetics' innovative technology to help biopharmaceutical companies accelerate drug development, reduce costs, and deliver more effective therapies
Read More
Gilead Sciences and Genesis Therapeutics Partner on AI-Driven Drug Discovery
What You Should Know:
- Gilead Sciences, a global biopharmaceutical company, and Genesis Therapeutics, an AI-focused biotechnology firm, have announced a strategic collaboration to discover and develop innovative small molecule therapies.
- The startegic partnership leverages Genesis' cutting-edge AI platform, GEMS, to accelerate drug discovery and development.
A Powerful Collaboration
Genesis Therapeutics' GEMS platform utilizes advanced AI techniques to generate and
Read More
The Role of AI in Streamlining Drug Discovery and Clinical Trials: A New Era in Pharmaceutical Innovation
In the rapidly evolving world of pharmaceuticals, artificial intelligence (AI) is emerging as a game-changer. From accelerating drug discovery to enhancing the efficiency of clinical trials, AI is revolutionizing how new medicines are brought to market. This transformation is not just limited to the research and development phases; AI is also playing a critical role in ensuring that drugs meet regulatory standards.
The AI Revolution in Drug Discovery
Drug discovery has traditionally been a
Read More
Quantiphi Invests in Transcell to Advance AI-Driven Drug Discovery
What You Should Know:
- Quantiphi, an AI-first digital engineering company, announced a strategic minority investment in Transcell, a pioneering stem cell-based biotech innovator. This collaboration marks a significant step forward in the integration of AI and biotechnology for drug discovery and development.
- By combining Quantiphi’s AI expertise with Transcell’s stem cell technology, the partnership aims to accelerate the development of innovative treatments while reducing
Read More
Absci and MSK Collaborate on Generative AI Drug Discovery
What You Should Know:
- Absci Corporation, a leader in generative AI drug creation, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop up to six novel cancer therapeutics.
- By combining Absci’s AI platform with MSK’s renowned cancer research expertise, the partnership aims to accelerate the discovery and development of new treatments for this devastating disease.
Absci's Integrated Drug Creation Platform
Absci's Integrated
Read More
Genomics plc Expands Drug Discovery Collaboration with Vertex
What You Should Know:
-Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company’s collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX) to use human genetics and machine learning to improve the discovery and development of new precision medicines.
-The partnership, which began in 2018, was previously extended in 2021. The collaboration will now run until 2026.
Vertex and
Read More
Athos Therapeutics Taps Vultr Cloud GPU to Power AI Drug Discovery Engine
What You Should Know:
- Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference.
- Powered by NVIDIA HGX H100 systems and running on Dell
Read More
